Rx Bandz, LLC SBIR Phase I Award, April 2021

A SBIR Phase I contract was awarded to Rx Bandz in April, 2021 for $49,434.0 USD from the U.S. Department of Defense and United States Air Force.

Overview Structured Data Issues Contributors Activity

sbir.gov/node/2172091

Is a

SBIR/STTR Awards

SBIR/STTR Award attributes

SBIR/STTR Award Recipient

Rx Bandz

Government Agency

U.S. Department of Defense

Government Branch

United States Air Force

Award Type

SBIR0

Contract Number (US Government)

FA8649-21-P-11660

Award Phase

Phase I0

Award Amount (USD)

49,4340

Date Awarded

April 14, 2021

End Date

July 19, 2021

Abstract

x Bandz’ innovative MiniJect™ auto-injector can be adapted to deliver epinephrine to Active Duty and beneficiaries prone to allergic reactions (anaphylaxis), as well as medics providing epinephrine when treating shock, cardiac arrest or respiratory distress. Its reduced size, weight, and ease-of-use means users can administer the right dose more reliably and quickly, no longer having to carry bulky, inconvenient auto-injectors. Furthermore, Rx Bandz’ epinephrine formulation aims to provide an increased shelf life over current auto-injectors.